NCT07704099Phase 2Recruiting

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Study sponsor: Keros Therapeutics, Inc. · KROS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-08-26Estimated
Enrollment · participants36Estimated
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.